Cystic fibrosis drugs that have the potential to save lives are rejected for use in Scotland

The Scottish Medicines Consortium have rejected Orkambi and Symkevi after hearing 'powerful testimonies'. Both drugs cost about £100,000 per year per patient that is eligible.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news